Burzynski SR Stolzmann Z Szopa B Stolzmann E Kaltenberg OP ANTINEOPLASTON A IN CANCER THERAPY (I) In: Physiol Chem Phys (1977) 9(6):485-500
Antineoplaston A (ANA), a peptide from human urine, was given to 21 patients with far-advanced tumors who were followed for 1-9 mo. Most were resistant to chemotherapy and/or radiotherapy. ANA caused complete remissions (CR) in 2/2 patients with Grade III transitional cell carcinomas of the bladder, 1/6 with advanced breast cancer, and a child with acute lymphoblastic leukemia. ANA caused partial remissions (PR) in 2/3 patients with chronic lymphocytic leukemia (CLL), 1/2 with rectal adenocarcinoma, and a 20-yr-old man with lung metastases from synovial sarcoma. Six patients (1 each with breast cancer, rectal adenocarcinoma, undifferentiated ovarian tumor, squamous cell carcinoma of the tongue or cervix, and Ewing's sarcoma) showed stabilization of disease (SD). The patients with tongue cancer and Ewing's sarcoma relapsed within about 2 mo. All of the PR patients and 4/6 SD patients were continuing to improve at the time of report. It was hoped that the SD patients would reach a PR and the PR patients a CR. Five patients died during treatment, but not of cancer or toxicity; 2/5 showed significant tumor regression at autopsy. ANA caused marked central necrosis of solid tumors. Most patients showed a transient increase of WBC and platelet counts after about 1 mo of treatment. Some had a febrile syndrome, apparently caused by tumor cell breakdown. The recommended treatment is continuous iv infusion (1.2 units/m**2/day, gradually increased to 33 units/m**2 or the development of fever) for about 1 mo, followed by lower doses (0.6 units, 2x/wk) im or rectally. ANA caused no significant toxicity at the doses used (0.6-33 units/m**2/day, iv, im, rectally, intrapleurally, intravesically, or topically). (14 Refs)
If one were to take Burzynski's word for it, this sounds pretty good. It's not necessary to do that because the interesting thing about this citation is that there was a site visit done in 1982 by a team of Canadian physicians at the request of the Ministry of Health in Ontario who made a point of following up on the cases of complete remission reported by Burzynski. The physicians were Blackstein and Bergsagel. Blackstein is a M.D. and a PhD and at the time of the visit was the head of the Division of Oncology at Mount Sinai Hospital in Toronto, as well as an associate professor at the University of Toronto. Daniel Bergsagel was a full professor of medicine at UofT and the Chief of Medicine at Princess Margaret Hospital. Several other physicians were consulted in the course of the development of this report. Here's the applicable portion:
"We made a point of asking Dr. Burzynski about the current status of the 4 patients who had achieved a complete remission. One was a 14-year-old boy with acute lymphoblastic leukemia who had been treated with a large dose of Methotrexate, and continued on Prednisone while Antineoplaston injections were given. Apparently he did improve with this therapy, but the remission lasted for only a few weeks, and he died 8 weeks later with recurrence of the leukemia. The clinical improvement likely resulted from the Methotrexate and Prednisone therapy given shortly before the Antineoplaston was started.
A patient with breast cancer was apparently free of disease when Antineoplaston was started. This patient shortly relapsed and has since died with metastatic breast cancer.
A patient with multiple bladder tumors was treated with Antineoplaston. The tumors have since recurred, and he has died of his disease.
The only surviving patient had a solitary bladder tumor. This type of bladder tumor is usually treated with cautery at the time of cystoscopy. Although Dr. Burzynski does not state this in his report, I suspect that this b ladder tumor disappeared as a result of the biopsy when he was cystoscoped. This patient is still alive."
This pretty much speaks for itself. Meanwhile, there is more in this report. The MDs asked Burzynski to present best examples chosen by him. Here are some comments on the cases Burzynski present3ed:
"The commonest problem we encountered was the fact that patients had received effective treatment before they were referred to Houston, and were responding slowly to this treatment. Dr. Burzynski started Antineoplaston, and falsely credited the Antineoplaston with the therapeutic response that was observed. We will quote two examples of this type of the problem:
1. A woman with Stage III carcinoma of the cervix had received full doses of radiation therapy to the pelvis prior to consulting Dr. Burzynski. When he saw her there was still some necrotic tumor in the cervix. A Pap. smear of the cervis showed extensive radiation changes in the epithelial cells, and possibly some carcinomatous cells, but the Cytologist could not be sure that there was viable tumor in the specimen he examined. The patient was started on Antineoplaston, the necrotic tumor gradually disappeared, and the epithellium of the vagina and cervix have healed, and the patient now feels very well. All of this improvement should be attributed to the prior radiation therapy rather than to the Antineoplaston therapy.
2. A patient with carcinoma of the prostate was found to have bone metastases on a bone scan. An orchiectomy was done two months before the patient was referred to Houston. The patient was started on Antineoplaston, and repeat bone scans at a later date showed improvement. A slow response such as this is characteristic of the orchiectomy response in patients with carcinoma of the prostate.
We were surprised that Dr. Burzynski would show us such questionable cases. We were left with the impression that either he knows very little about cancer and the response of different tumors to radiation and hormonal measures, or else he thinks that we are very stupid, and he has tried to hoodwink us.
As we look back over the cases were were shown, we are left with the impression that the only patients who are still alive either had slowly growing tumors, or had received effective treatment before being referred to Houston."
The conclusions of the Canadian site visit time were summarized as:
"After reviewing 20 case reports, selected by Dr. Burzynski as his best examples of clear cut responses to Antineoplastons we were unable to identify a single case in which therapeutic benefit could be attributed to Antineoplaston."
"We believe that it is unethical to administer unproven agents such as Antineoplastons to patients without satisfying the requirements of the FDA and an ethics committee, that the minimum standards for human experimentation are being met. We also believe that it is immoral to charge patients for this unproven, experimental treatment."